Rhombotin-2 (RBTN-2) is a proto-oncogene only in the context transcription factors. For example, RBTN-2 has recently been of T lymphocytes. We postulated that the oncogenic effect of shown to bind erythroid transcription factors tal-1, GATA-1,
factors. RBTN-2 binds other proteins via its two tandem LIM domains, which make up approximately two-thirds of its mass

Introduction
(reviewed in Ref. 11) . Each LIM domain coordinates two zinc cations, which presumably hold the intervening residues in The proto-oncogene rhombotin-2 (RBTN-2) was initially loop-like structures reminiscent of zinc finger domains. The implicated in T cell leukemogenesis by the high frequency of residues required for zinc cation-coordination and structural non-random chromosomal translocations involving the RBTNintegrity are highly conserved. The other amino acid residues, 2 locus (at 11p13) in childhood T cell acute leukemia. 1, 2 and to some degree the length of the LIM domain loop porThese translocations almost invariably result in the high tions are variable, and thus confer each LIM domain its own expression of RBTN-2 in T cells where RBTN-2 is not normally specific function. LIM domains have been shown to facilitate expressed. 2, 3 Recent transgenic studies have confirmed the a variety of protein-protein interactions. 9, 12, 13 For example, role of RBTN-2 as a proto-oncogene. Enforced expression of the LIM domains of RBTN-2 mediate its binding to tal-1 13 and RBTN-2 in T cells of transgenic mice results in T cell lym-RBP2 (Mao S, Neale GAM, Bram RJ, Goorha RM, submitted). phoma and leukemia. [4] [5] [6] The oncogenic effects of RBTN-2 are Thus, RBTN-2's functions are likely mediated by specific pro-T cell specific. Transgenic mice overexpressing RBTN-2 in all tein-protein interactions through its LIM domains. tissues do not show any type of cancer other than T cell
Although it is clear that the inappropriate expression of leukemia/lymphoma. 6 The inappropriate expression of RBTN-RBTN-2 in T cells results in leukemia, the molecular 2 in thymocytes causes proliferation of immature T cells prior mechanism(s) of this are not yet understood. Because RBTNto overt leukemia/lymphoma. 5, 6 2 exerts its normal functions by binding to different proteins, In addition to its involvement in T cell leukemia/lymphoma, it seemed reasonable to evaluate whether RBTN-2's involve-RBTN-2 plays multiple roles in normal cellular functions. The ment in T cell leukemia is also mediated via specific proteinwide tissue distribution and varying cellular location of RBTNprotein interactions. The over-expression of RBTN-2 in trans-2 is consistent with its being a multi-functional protein. 7 The genic mice results in only one type of cancer: T cell pattern of expression of RBTN-2 in tissues is strikingly similar leukemia/lymphoma. For this reason, we hypothesized that T to that of metallothionein, suggesting a role for RBTN-2 in the cells possess a unique pattern of RBTN-2 binding protein(s). acute phase response. 7 In addition, a function for RBTN-2 in The T cell environment could differ from that of other tissues erythropoiesis is known: homozygous null mice lacking in the identities and/or relative amounts of different RBTN-2 RBTN-2 die in utero at approximately day 11 due to lack of binding proteins. To identify these proteins we screened a red blood cell formation. 8 The multiple functions of RBTN-2 mouse thymic tumor cDNA library using the yeast two-hybrid may be mediated via binding to other proteins, particularly system. From this screening we identified elf-2, a novel member of the elf subfamily of ets transcription factors. We found two isoforms of elf-2, denoted elf-2a and elf-2b, which have forms have different, and perhaps opposite effects on the same BNN132 as described. 16 pACT 2 -P253 plasmid DNA was prepared and purified by CsCl density gradients. 17 target genes.
Two-hybrid screening
Materials and methods
The general procedure of library screening by the yeast twoPlasmids hybrid assay was performed as described.
14 Y190 yeast was co-transformed with pAS 2 -R 2 ⌬N (50 g) and pACT 2 -P253 The yeast two-hybrid vectors ACT 2 and pAS 2 were genercDNA library (50 g), and then selected for growth on SD ously provided by Dr Stephen Elledge, Baylor College of minimal media lacking histidine, leucine, and tryptophan, but Medicine, Houston, TX, USA. The full length mouse RBTN-2 containing 50 mm histidine synthesis inhibitor 3-AT (3AT sequence is 158 amino acids. The following RBTN2 deletion Media). Positive colonies were screened for ␤-galactosidase mutants were generated by PCR and ligated into pAS 2 :R 2 ⌬N activity by filter lift assay. Double positive (HIS + , ␤-gal + ) col-(RBTN-2 amino acids 27-158); R 2 L 1 L 2 (RBTN-2 amino acids onies were subjected to an additional round of growth selec-27-150); R 2 L 1 (RBTN-2 amino acids 27-86) and R 2 L 2 (amino tion on 3AT Media, and re-assayed for ␤-galactosidase. pACTacids 92-150). The pBS-R2 construct 6 contains the entire P253 plasmids were isolated from double positive colonies coding sequence of mouse RBTN-2 under control of the T7 and evaluated. Based on Northern blot analyses, one clone, promoter in pBluescript II (Stratagene, La Jolla, CA, USA).
pACT 2 -C69, was chosen for further study. To delimit the GST-C69 and GST-C69 tr fusion proteins were expressed in E.
regions of RBTN-2 required for binding to pACT 2 -C69 Y190 coli using pGEX4T expression vectors (Pharmacia Biotech, yeast was co-transformed with pACT 2 -C69 and pAS 2 -R 2 ⌬N, Uppsala, Sweden). A PCR product corresponding to C69 pAS 2 -R 2 L 1 L 2 , pAS 2 -R 2 L 1 , or pAS 2 -R 2 L 2 and selected for growth (encoding elf-2a amino acids 426-538) was ligated into the on SD lacking leucine and tryptophan. Transformants were SalI site of pGEX4T3. C69 tr , the 266 bp 5′ XhoI fragment of then assayed for ␤-galactosidase activity using a filter lift the pACT 2 -C69 insert, was ligated into the XhoI site of assay. pGEX4T2. The fidelity of all PCR-generated constructs were verified by direct dideoxy sequence analyses.
Isolation of elf-2 clones Cell lines and yeast
The ACT 2 -P253 library was screened using the 564 bp cDNA insert from pACT 2 -C69. The largest clones, clone 2 and clone All cell lines were grown in RPMI 1640 medium sup-9 ( Figure 2 ), were identified and sequenced completely. To plemented with 10% FCS, 2 mm glutamine, and 50 mg/ml obtain sequence information at the 5′ end of elf-2, we gentamycin sulfate. The following human cell lines were studemployed two strategies. First, we re-screened the P253 ied: the erythroleukemia cell line K562, the myeloid cell line library using a 5′ probe from a human elf-2 cDNA clone. This HL-60; the undifferentiated cell line DU-528, and the B cell strategy identified the mouse elf-2 clone 1-2. Second, we line Raji. Human thymuses were obtained from children aged amplified aliquots of the ACT 2 P253 cDNA library 2-5 years undergoing cardiac surgery; thymocytes were pre-(3.5 × 10 8 p.f.u.) using one primer (pACT-5′: 5′-CTATCpared by gentle homogenization of thymus tissue followed by TATTCGATGATGAAG-3′) corresponding to sequences within centrifugation on a density gradient (Lymphoprep, Nycomed, the ACT 2 vector, and another primer corresponding to Norway). The mouse T cell line P253 was established from a nucleotides 251-274 of clone 1-2 ( Figure 3b ). This amplifithymic tumor from a RBTN-2 transgenic mouse. 6 cation was then followed by a secondary amplification using Yeast strain Y190 (MATa, leu2-3, 223 ura3-12, trp1-901, his the same vector primer plus a nested primer corresponding to 3-D200, ade2-101, gal4Dgal80D URA3 GAL-lacZ, LYS GALnucleotides 229-249 of clone 1-2. Following an initial denat-HIS3, cyh r ) was a gift from Dr Stephen Elledge. Yeast was uration of 94°C for 150 s, each amplification consisted of 35 grown on YPAD medium, or SD minimal medium supcycles of the following: 94°C for 45 s; 60°C for 30 s; 72°C plemented as described. 14 for 180 s. The longest product detected (ෂ700 bp) was cloned (PCR700) and six independent clones were sequenced. Since the sequences of PCR700 and clone 9 did not overlap, direct Construction of the pACT 2 -P253 cDNA library amplification of the ACT 2 -P253 library was performed to identify sequences between the two clones. Primers corresponding to nucleotides 436-456 and 726-746 of elf-2a The strategy used for cDNA library construction was essentially as described previously. 15, 16 Poly(A) + mRNA was pur-( Figure 3a) were used in the amplification. A single product of 310 bp was identified and cloned (PCR300). Six independent ified from P253 total RNA using a Poly A Quick Kit (Stratagene). For first strand cDNA synthesis, a combination clones of PCR300 were sequenced. The sequence of this clone was identical to nucleotides 436-746 of the elf-2a of oligo-dT and random oligonucleotides were used to prime 5 g of poly(A) + mRNA using a Timesaver cDNA synthesis kit sequence and provided confidence in the fidelity of the elf-2 sequences taken from the overlapping portions of clone 1-2 (Pharmacia Biotech). After second strand synthesis, cDNA was blunt-ended, and then ligated to oligonucleotide adapters as and clone 9. All sequencing was done on an Applied Biosystems 373 described. 15 Size-selected cDNA (Ͼ500 bp) was ligated into XhoI digested, and T-filled ACT 2 vector arms. 15 Recombi-DNA sequencer (Perkin Elmer/Applied Biosystems Division, Foster City, CA, USA) using dye terminators. 18 The complete nants were packaged using Gigapack III Gold Packaging Extracts (Stratagene). A total of 1.6 × 10 7 recombinants were sequences for elf-2a and elf-2b were assembled using Genetics Computer Group (GCG) software (Madison, WI, USA). obtained. Automatic conversion of the ACT 2 -P253 mouse library into plasmid was accomplished in the bacterial strain Sequence comparisons were performed using the Bestfit pro- 
gram (GCG). Identification of putative exon-exon junctions
Reduced stringency of hybridization and washing was used when the pACT 2 -C69 probe was hybridized to the human cell within the cDNA sequences was performed using the software RNASPL (Department of Cell Biology, Baylor College of blot: hybridization was performed at 42°C in 35% formamide containing 6 × SSC pH 7.0, 1% SDS, 0.1% Ficoll, 0.1% polyMedicine).
vinylpyrrolidone, 0.1% bovine serum albumin, and 100 mg/ml salmon sperm DNA. Washing was performed three times at room temperature in 2 × SSC-0.1% SDS, with a final
Northern blot analyses wash at 54°C in 0.43 × SSC-0.1% SDS. An elf-2a-specific probe, corresponding to nucleotides 1-435 of elf-2a, was genTotal cellular RNA was extracted using the guanidine/CsCl method. 19 Northern blots containing 20 g of total RNA per erated by PCR using the PCR700 clone as template. The ␤-actin probe was as described previously. 20 32 P-labeled probes lane were prepared and treated as previously described. 20 The C69 probe, corresponding to nucleotides 1474-2107 of elf-2a
were prepared by random priming using a Decaprime labeling kit (Ambion, Austin, TX, USA). The relative amounts of the elf-( Figure 3a ) was prepared by digesting pACT 2 -C69 with BglII.
Figure 2
Diagrammatic representation of overlapping elf-2 clones isolated from the mouse P253 cDNA library. Open boxes depict untranslated regions at the 5′ and 3′ ends, while the shaded boxes depict coding sequences. The filled boxes represent coding sequences that are identical between in elf-2a and elf-2b. Unique sequences for elf-2a and elf-2b are indicated by striped boxes, and dotted boxes, respectively. The numbers on top of the partial cDNA clones indicate the beginning and end points of the clones relative to the entire elf-2a sequence which is depicted topmost in the figure. The melded sequence for elf-2b is represented at the bottom of the figure. Numbers over the elf-2b clone reflect the first and last nucleotides, as well as the nucleotide positions at which the coding sequence starts and ends. 2a and elf-2b bands were quantitated by densitometry analysis from a T cell line (P253) derived from a RBTN-2 transgenic mouse thymic tumor. In the yeast two-hybrid system for using a Kodak Biomage system. determining protein-protein interactions, the bait and target proteins are fused to the DNA binding and transcription activation domains of the yeast GAL4 protein, respectively. Yeast
In vitro binding assays Y190 cells were co-transformed with the RBTN-2 bait (pAS 2 -R 2 ⌬N) and the P253 transgenic mouse thymic tumor cDNA 35 S RBTN-2 was prepared from plasmid pBS-R2 using an in vitro transcription/translation kit (Promega) and 35 S cysteine library (pACT 2 -P253). This yeast strain contains the reporter genes HIS3 and lacZ under the control of the GAL4 regulatory (Amersham, Arlington Heights, IL, USA) under conditions specified by the suppliers. The inserts in pGEX4T3-C69 and sequences. The transformants were placed under growth selection for histidine production followed by a filter-lift assay pGEX4T2-C69 tr were expressed as GST fusion proteins in E. coli and purified as described. 21 Fusion proteins were of the for ␤-galactosidase activity. Yeast clones positive by both criteria were further evaluated. The positive pACT 2 -P253 clones expected size as detected by silver staining of SDS-PAGE gels (data not shown). Equal amounts of fusion proteins were were isolated and used to examine the tissue distribution of corresponding RNA transcripts, as well as the RBTN-2 binding bound to glutathione-sepharose beads and then incubated with 35 S RBTN-2 for 1 h at 4°C with gentle rocking. The beads specificity of the peptides encoded by each insert. One positive clone, pACT 2 -C69, was chosen for further analyses based were then washed six times with cold buffer (20 mm Tris-Cl pH 8.0, 100 mm NaCl, 1 mm EDTA, 0.5% NP-40), boiled in on its pattern of expression in T cells. Sequence analyses and subsequent data base searches did not reveal any known pro-SDS-PAGE loading buffer, and the supernatant loaded onto a 12% SDS polyacrylamide gel. Following electrophoresis, gels teins identical to that encoded by the pACT 2 -C69 insert. were soaked in 16% sodium salicylate for 30 min, and then exposed to X-ray film.
T cell specific expression of pACT 2 -C69 RBTN-2 is a proto-oncogene only in the context of T lymphoResults cytes. Thus, we reasoned that proteins involved in RBTN-2-mediated T cell leukemogenesis would display a pattern of
Isolation of a RBTN-2 binding protein from a T cell library expression unique to thymocytes. To evaluate the expression of the RBTN-2 binding peptide in pACT 2 -C69, the 564 bp cDNA insert was used as a probe in Northern blot analyses To identify T cell-specific RBTN-2 binding proteins, we used the yeast two-hybrid system to screen a cDNA library made (Figure 1a , panels 1 and 2). Two transcripts of about 3.5 kb that the high expression of C69 mRNA in thymocytes was due to increased expression of the 3.5 kb transcript. Thus, while amounts of both transcripts were detected in spleen, brain, lung, liver, kidney, intestine, pancreas, heart and skeletal musthe 3.8 kb transcript was expressed approximately equally in all tissues (Figure 1a , panel 3), thymocytes had increased cle. However, thymocytes and bone marrow expressed significantly higher amounts of C69 mRNA as compared to other expression of the 3.5 kb transcript. Expression levels in blood and lymph node could not be evaluated because of the low tissues ( Figure 1a, panel 2) . The same Northern blot was exposed for different times (Figure 1a, panels 1 and 2 ) to show yield of RNA from these tissues, as indicated by the ethidium bromide-stained gel (Figure 1a, panel 4) . The relative levels of were obtained (elf-2a and elf-2b shown at the top and bottom of Figure 2 , respectively). These final cDNA sequences were the transcripts were quantitated by densitometry, and while some variation was observed between different sample prepderived from partial cDNA clones, and their positions relative to the final cDNA sequences are indicated in Figure 2 . Three arations, thymocytes reproducibly showed a substantial difference in the ratio of the two transcripts when compared with clones (clone 1-2, clone 2 and clone 9) were obtained by conventional screening. However, a PCR-based approach (as other tissues. In different experiments, the ratio of the 3.5 kb to 3.8 kb transcript in thymocytes varied between 4:1 and described in Materials and methods) was used to identify clones representing alternative 5′ ends. The longest product 10:1. In contrast, the ratio in all other tissues was between 1:1 and 2:1 ( Figure 1a , and data not shown).
of this amplification, PCR700 (Figure 2 ), was cloned and sequenced. Sequence data showed that the 3′ portion of clone Because RBTN-2 is highly conserved between species, 1, 2 and promotes T cell leukemia in both mouse and humans, we PCR700 was identical to part of clone 1-2, while the 5′ region was unique. Thus, it appeared we had isolated clones repevaluated whether a human homolog of the pACT 2 -C69 cDNA also existed. Human hematopoietic cell lines were anaresenting the two different mRNA transcripts seen by Northern blot analyses (Figure 1 ). lyzed for expression of pACT 2 -C69 transcripts under low stringency conditions (Figure 1b, upper) . Similar to mouse tissues, By melding the common sequences of PCR700 with clone 1-2, clone 2 and clone 9, we obtained a final cDNA sequence two transcripts of 3.5 and 3.8 kb were detected in human cells. The thymocyte-specific ratio of the transcripts paralleled of 2652 bp (Figure 2 , top; Figure 3a) . As described below, this sequence was named elf-2a. A second sequence of 2406 bp that observed in mice. The B cell line Raji, the myeloid cell line HL-60, and the erythroid leukemia cell line K562 had (Figure 2 , bottom) was obtained by melding the sequences of clone 1-2, clone 9 and clone 2. This composite sequence was ratios between 1:1 and 2:1 for the 3.5 kb and the 3.8 kb transcripts. In contrast, human thymocytes expressed a four-fold named elf-2b. The sequences of elf-2a and elf-2b differ only at their 5′ ends, and the site of divergence, as well as the greater amount of the 3.5 kb transcript than the 3.8 kb transcript (Figure 1b , upper, and data not shown). The 3.5 kb tranoverlap between clones 1-2 and PCR700, is shown diagrammatically in Figure 2 , and in detail in Figure 3b . script also appeared to predominate in the undifferentiated hematopoietic cell line DU-528. However, the C69 mRNA
The composite sequences for elf-2a and elf-b predict proteins of 581 and 521 amino acids, respectively. Both was expressed at such low levels in this cell line that accurate quantitation of the transcripts was not possible. The sequences are flanked by untranslated regions, indicating that the entire coding regions have been identified. The initiating expression of the C69 mRNA relative to ␤-actin mRNA (Figure 1b , lower) in these cell lines suggested that the C69 AUG residues of both transcripts are in good context for efficient translation. 22 In the sequence common to both trantranscripts were expressed in higher amounts in thymocytes than in the other hematopoietic lineages tested. These data scripts, the portion corresponding to pACT 2 -C69 comprises the coding sequence for the 155 carboxyl terminal amino acid indicated that a human homolog of the RBTN-2 binding protein existed, and that this homolog had the same pattern of residues, and extends into the 3′ untranslated region (Figure 3a) . Thus, both transcripts are predicted to encode proexpression as in mouse. These findings were reassuring because any protein involved in RBTN-2-mediated T cell leuteins with carboxyl-terminal RBTN-2 binding domains. Each transcript also encodes an identical ets family DNA-binding kemogenesis would likely share the same pattern of expression in mouse and human since RBTN-2 has demondomain (Figure 3a) . The common DNA-binding motif is virtually identical to that of the ets transcription factor elf-1 strated potential to cause leukemia in both species.
( Figure 4a ). The deduced amino acid sequences of the elf-1 and elf-2 DNA-binding motifs vary by only 1 out of 41 residues, and this substitution is conservative (Figure 3a) . On the Elf-2: a novel ets protein with two isoforms basis of the homology between the DNA-binding regions we named the newly-identified gene elf-2. The key features of the To isolate cDNA clones representing the 3.5 kb and 3.8 kb transcripts, the P253 mouse thymic tumor cDNA library was elf family proteins are summarized in the diagram (Figure 4b ). The two elf-2 cDNA sequences vary only at their aminoscreened. From this screening two cDNA sequences which represent the coding regions of the 3.5 and 3.8 kb transcripts
termini. The longer sequence, denoted elf-2a, contains a unique 79-residue amino terminus that is rich in glutamate Elf-2a is encoded by the 3.8 kb transcript and aspartate (Figure 4a ). Elf-2b contains 19 unique residues at its amino terminus. Elf-2a shares three additional short
The pACT 2 -C69 probe hybridized to both elf-2a and elf-2b transcripts in Northern blots (Figure 1a , panels 1 and 2). To pockets of homology with elf-1 in addition to the DNA binding domain. Elf-2b contains only the most carboxyl-terminal determine the identities of the cDNAs isolated, the same blot was stripped and hybridized with a probe from the 5′ unique of these three homologous segments. The transcripts encoding the elf-2a and elf-2b isoforms most likely arise from alternative region of elf-2a (Figure 1a, panel 3 ). This elf-2a specific probe hybridized exclusively to the 3.8 kb transcript, indicating that splicing. There are two potential splicing sites near the points of divergence between the transcripts for elf-2a and elf-2b.
the longer cDNA sequence (elf-2a) was encoded by the larger transcript, and that all tissues had similar levels of this tranHowever, the possibility of separate genes cannot yet be formally ruled out.
script. Northern analysis using a probe specific for elf-2b was unique in that they express a four-to 10-fold greater amount of the 3.5 kb elf-2b transcript than the 3.8 kb elf-2a transcript. In contrast, all other tissues express roughly equal amounts of two elf isoforms.
Both LIM domains of RBTN-2 are required for binding elf-2
To characterize the regions of RBTN-2 required for binding to elf-2, we evaluated the interaction of deletion mutants of RBTN-2 with -C69 in yeast. A positive interaction was scored by blue color production from the ␤-galactosidase filter assay ( Figure 5a ). As expected, positive results were obtained when yeast was co-transformed with pACT 2 -C69 and pAS 2 -R 2 ⌬N, the construct encoding the RBTN-2 amino-terminal deletion mutant which was used initially in the two-hybrid screening (Figure 5a, quadrant 1) . Positive results were also obtained when yeast was co-transformed with pACT 2 -C69 and pAS 2 -R 2 L 1 L 2 , a deletion construct encoding only the LIM domains of RBTN-2 ( Figure 5a , quadrant 3). However, no binding was seen when yeast was co-transformed with pACT 2 -C69 and plasmids encoding either the amino-terminal (pAS 2 -R 2 L 1 ), or the carboxyl-terminal (pAS 2 -R 2 L 2 ) LIM domains of RBTN-2 ( Figure 5 , quadrants 2 and 4, respectively). These data indicated that both LIM domains of RBTN-2 are necessary and sufficient for binding to elf-2.
To verify the RBTN-2/elf-2 interaction by an independent method, the insert from pACT 2 -C69, corresponding to elf-2a amino acids 426-581, was cloned into pGEX4T3 to produce a glutathione-S-transferase (GST) fusion protein (GST-C69). After expression in E. coli, the fusion protein was immobilized on sepharose beads and incubated with in vitro translated 35 S RBTN-2. Bound RBTN-2 was detected by SDS polyacrylamide electrophoresis followed by autoradiography (Figure 5b ). As expected, 35 S RBTN-2 was not retained when incubated with glutathione sepharose beads alone (Figure 5b, lane 1) , or when incubated with GST alone produced by the empty vec- 
Discussion
The arrow marks the expected size of RBTN-2 (ෂ18 kDa). A portion of untreated in vitro translated tion factors in a wide variety of species ranging from Drosophila to humans (for review see Refs 23 and 24). Ets transcription factors have been implicated in a variety of also performed (data not shown). Unfortunately, these blots were difficult to interpret because of high background, most developmental processes, including growth and differentiation. In our search for proteins involved in mediating RBTNlikely due to the high G/C content of the 5′ unique portion of elf-2b. Nevertheless, we are confident that the 3.5 kb tran-2-associated T cell oncogenesis, we identified a novel ets transcription factor which has homology to elf-1. 25, 26 This new ets script encodes the shorter isoform (elf-2b) because the pACT 2 -C69 probe hybridizes to both the 3.5 kb and 3.8 kb transcripts protein contains a DNA-binding domain that is 98% identical to that of elf-1. There are two distinguishing features between (Figure 1, panels 1 and 2) whereas the elf-2a probe binds only the 3.8 kb transcript (Figure 1a, panel 3) 6 A likely explanation of this observation is that the expression of elf-1 and elf-2a/b would confer their ability to respond to different regulatory signals. For example, binding to Rb may india RBTN-2 partner is different in T cells vs other tissues. Indeed, elf-2 has a unique pattern of expression in T cells. In all cate a role for elf-1 in cell cycle progression. Thus, while the target genes of the elf family are expected to be the same, due tissues, the two isoforms of elf-2 are expressed in roughly equal amounts, however, in thymocytes the elf-2b isoform to their homologous DNA-binding domains, the expression of these genes would be activated through different regulatory predominates. (2) Elf-2 appears to be a transcription factor with its own DNA-binding domain. Since RBTN-2 is nuclear signals.
Since we identified elf-2a/b through its binding to RBTN-2 when expressed in hematopoietic cells, but lacks any identifiable DNA-binding motif or nuclear localization signal, it we further examined the interaction between these proteins. Yeast two-hybrid assays showed that both LIM domains of must associate with a partner which contains both of these domains. Elf-2 fulfills both these criteria. (3) Elf-2 is most likely RBTN-2 were required for binding to elf-2. Neither LIM domain alone was sufficient to support the interaction. This involved in T cell differentiation and proliferation. The nearly identical DNA-binding domains of elf-1 and elf-2 strongly finding contrasts with that of Mao et al, where the carboxylterminal LIM domain of RBTN-2 is sufficient for its binding to suggest the elf proteins regulate the same target genes, several of which (eg IL-2, IL-2 receptor, CD4) are regulated during T RBP2, and illustrates RBTN-2 has different binding sites for its different protein ligands. The yeast two-hybrid assays were cell maturation/proliferation. Thus, the interaction between elf-2 and RBTN-2 provides a mechanism by which the corroborated by in vitro binding assays; these assays delimited the RBTN-2 binding region to a 88 amino acid region near inappropriate expression of RBTN-2 T-cells may affect the regulation of T cell development. the carboxyl terminus of elf-2a/b.
In view of the association of elf-1 with T cell proliferThe mechanism of elf-2 action is not known, but as previously discussed, it seems likely that the elf-2 isoforms have ation/differentiation, [25] [26] [27] [28] the homology between elf-1 and elf2a/b is intriguing. Elf-1 most likely has a role in T cell differendifferent, perhaps opposite functions in T cell development. Perhaps the interaction between elf-2b and RBTN-2 in thymotiation or activation since its level of expression is increased by treatment of cells with phorbol ester. 25 Furthermore, sevcytes blocks differentiation, or alternately, promotes proliferation and leukemogenesis. Support for this hypothesis can be eral genes important in T cell differentiation have elf-1 target sequences in their regulatory regions, eg IL-2, 26 IL-2 recepdrawn from observations that alternatively spliced products of other transcription factors are known to have opposing biotor, 27 and CD4 28 genes. Elf-1 and elf-2a have three short homologous stretches that are amino-terminal to their DNA-bindlogical effects. For example, the alternatively spliced bcl products bcl-X L and bcl-X S inhibit and promote apoptosis, ing domains (Figure 4a ). The most amino-terminal two of these pockets of homology are part of an acidic, putative respectively. 47 However, more relevant to our findings is the acute myeloid gene (AML1). AML1 shares several features transactivation domain. These regions may confer transactivation activities to elf-1 and elf-2a. In contrast, elf-2b does not with elf-2. Alternative splicing of AML1 results in transcripts encoding the AML1a and AML1b proteins. 48, 49 Both isoforms contain the putative transactivation domain because the unique amino-terminal region of elf-2a is replaced by a 19 have identical DNA binding domains, but unlike AML1b, AML1a lacks a transactivation domain. The overexpression of residue stretch in elf-2b (Figure 4a ). Since elf-2a and elf-2b contain identical DNA-binding and RBTN-2 binding domains, AML1a suppresses granulocytic differentiation and stimulates cell proliferation in murine myeloid cells. 49 However, the prothese isoforms most likely recognize the same DNA binding motif and are probably controlled by the same regulatory liferative effects of AML1a can be negated by the concomitant overexpression of AML1b. In the case of elf-2, we envision a pathways. However, the differences in the amino terminal portions of elf-2a and elf-2b suggest that these isoforms have model in which the opposing effects of RBTN-2/elf-2a and RBTN-2/elf-2b balance each other in most tissues. In contrast, different, perhaps opposing, effects.
In addition to normal functions in cell proliferation and difthymocytes, which do not normally express RBTN-2, have a relatively high elf-2b: elf-2a ratio. The inappropriate ferentiation, the inappropriate expression of ets genes caused by chromosomal translocations or retroviral insertional expression of RBTN-2 in thymocytes would therefore result in the formulation of a disproportionate number of RBTN-2/elfmutagenesis has been linked to numerous malignancies. In fact, the first-discovered member of the ets gene family, v-ets, 2b complexes. Perhaps this 'unbalanced' interaction of RBTN-2 with elf-2b promotes the proliferation of immature T cells. was identified as a part of the gag-myb-ets fusion oncogene of the transforming avian retrovirus E26. 29, 30 Murine erythroleukemias are associated with the retroviral insertional activation of ets proto-oncogenes spi-1 31 or fli-1. 32 Several cancers involve chromosomal translocations that produce fusion Acknowledgements proteins containing ets proteins. For example, acute myeloid leukemia has been associated with translocations yielding chimeras of Fus and the ets protein Erg. 33 The Ewing family We are grateful to Ramona Tirey, Josie Harris-Chambers, and Karen Honeycutt for their excellent technical assistance. This of sarcomas and tumors are associated with different chromosomal translocations resulting in one of several EWS/Ets prowork was supported in part by Cancer Center Support CORE grant, P30 CA 21765, and by CA 43277, and by the American tein chimeras.
34-41 Chromosomal translocations involving the ets member tel are associated with B lineage acute leukemias, Lebanese Syrian Associated Charities (ALSAC).
